These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 12108974)

  • 1. Cancer immunotherapy using gene-modified dendritic cells.
    Ribas A; Butterfield LH; Glaspy JA; Economou JS
    Curr Gene Ther; 2002 Feb; 2(1):57-78. PubMed ID: 12108974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetically modified dendritic cells in cancer therapy: implications for transfusion medicine.
    Foley R; Tozer R; Wan Y
    Transfus Med Rev; 2001 Oct; 15(4):292-304. PubMed ID: 11668436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MHC class II presentation of endogenously expressed antigens by transfected dendritic cells.
    Diebold SS; Cotten M; Koch N; Zenke M
    Gene Ther; 2001 Mar; 8(6):487-93. PubMed ID: 11313828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic cells.
    Okada N; Saito T; Masunaga Y; Tsukada Y; Nakagawa S; Mizuguchi H; Mori K; Okada Y; Fujita T; Hayakawa T; Mayumi T; Yamamoto A
    Cancer Res; 2001 Nov; 61(21):7913-9. PubMed ID: 11691812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lentivirally transduced dendritic cells as a tool for cancer immunotherapy.
    Breckpot K; Dullaers M; Bonehill A; van Meirvenne S; Heirman C; de Greef C; van der Bruggen P; Thielemans K
    J Gene Med; 2003 Aug; 5(8):654-67. PubMed ID: 12898635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From pathogen to medicine: HIV-1-derived lentiviral vectors as vehicles for dendritic cell based cancer immunotherapy.
    Dullaers M; Thielemans K
    J Gene Med; 2006 Jan; 8(1):3-17. PubMed ID: 16288497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitization to enhanced green fluorescence protein minor histocompatibility antigen by gene transduction into dendritic cells and peritoneal exudate macrophages.
    Satoh E; Li XK; Hara Y; Ogata K; Guo L; Kitazawa Y; Funeshima-Fuji N; Satoh T; Miyagi T; Sugiura W; Yamamoto N; Teramoto K; Arii S; Kimura H
    Transpl Immunol; 2007 Nov; 18(2):73-84. PubMed ID: 18005848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetically modified dendritic cells for cancer immunotherapy.
    Ribas A
    Curr Gene Ther; 2005 Dec; 5(6):619-28. PubMed ID: 16457651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feeding dendritic cells with tumor antigens: self-service buffet or à la carte?
    Melero I; Vile RG; Colombo MP
    Gene Ther; 2000 Jul; 7(14):1167-70. PubMed ID: 10918484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene-modified dendritic cells for immunotherapy against cancer.
    Lundqvist A; Pisa P
    Med Oncol; 2002; 19(4):197-211. PubMed ID: 12512913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficient gene delivery into dendritic cells by fiber-mutant adenovirus vectors].
    Okada N
    Yakugaku Zasshi; 2001 Aug; 121(8):593-600. PubMed ID: 11523120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of tumor-specific T cells by dendritic cells expressing the NY-ESO-1 antigen after transfection with the cationic lipophosphoramide KLN5.
    Le Gallo M; Toutirais O; Montier T; Cabillic F; Bouet F; Delépine P; Lehn P; Jotereau F; Catros V
    J Gene Med; 2008 Jun; 10(6):628-36. PubMed ID: 18338820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isolation and Characterization of an HLA-DRB1*04-Restricted HPV16-E7 T Cell Receptor for Cancer Immunotherapy.
    Mercier-Letondal P; Marton C; Deschamps M; Ferrand C; Vauchy C; Chenut C; Baguet A; Adotévi O; Borg C; Galaine J; Godet Y
    Hum Gene Ther; 2018 Oct; 29(10):1202-1212. PubMed ID: 30136612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.
    Xia D; Moyana T; Xiang J
    Cell Res; 2006 Mar; 16(3):241-59. PubMed ID: 16541123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic cell-tumor cell hybrids and immunotherapy: what's next?
    Cathelin D; Nicolas A; Bouchot A; Fraszczak J; Labbé J; Bonnotte B
    Cytotherapy; 2011 Aug; 13(7):774-85. PubMed ID: 21299362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Presentation of tumor antigens by dendritic cells genetically modified with viral and nonviral vectors.
    Lotem M; Zhao Y; Riley J; Hwu P; Morgan RA; Rosenberg SA; Parkhurst MR
    J Immunother; 2006; 29(6):616-27. PubMed ID: 17063124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination.
    Chan T; Sami A; El-Gayed A; Guo X; Xiang J
    Gene Ther; 2006 Oct; 13(19):1391-402. PubMed ID: 16724093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bacillus Calmette-Guérin cell-wall skeleton enhances the killing activity of cytotoxic lymphocyte-activated human dendritic cells transduced with the prostate-specific antigen gene.
    Fujii R; Iwahashi M; Kikkawa K; Inagaki T; Kohjimoto Y; Ojima T; Mori T; Kuramoto T; Nishizawa S; Azuma I; Yamaue H; Shinka T; Hara I
    BJU Int; 2009 Dec; 104(11):1766-73. PubMed ID: 20063450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of tumor-reactive CTL against the tumor-associated antigen HER2 using retrovirally transduced dendritic cells derived from CD34+ hemopoietic progenitor cells.
    Meyer zum Büschenfelde C; Nicklisch N; Rose-John S; Peschel C; Bernhard H
    J Immunol; 2000 Oct; 165(7):4133-40. PubMed ID: 11034426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dendritic-tumor fusion cells in cancer immunotherapy.
    Takakura K; Kajihara M; Ito Z; Ohkusa T; Gong J; Koido S
    Discov Med; 2015 Mar; 19(104):169-74. PubMed ID: 25828520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.